Pfizer’s pursuit of AstraZeneca was hanging by a thread yesterday after its “final” £69.4bn offer was rejected by the UK company, sparking recriminations between the rival drugmakers and shareholders.
辉瑞(Pfizer)对阿斯利康(AstraZeneca)的收购昨日悬于一线，此前该公司提出的694亿英镑“最终”收购要约被阿斯利康拒绝，引发这两家互为竞争对手的制药商及其股东间的相互攻讦。
您已阅读20%（294字），剩余80%（1157字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。